12/4
07:03 am
maze
Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.
12/3
10:09 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/25
09:46 am
maze
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]
Low
Report
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]
11/15
10:33 am
maze
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
11/15
01:42 am
maze
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at
Wall Stree
11/13
06:12 pm
maze
Maze Therapeutics (NASDAQ:MAZE) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.
11/7
10:27 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at Wedbush from $35.00 to $36.00. They now have an "outperform" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at Wedbush from $35.00 to $36.00. They now have an "outperform" rating on the stock.
11/6
04:11 pm
maze
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights [Yahoo! Finance]
Low
Report
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights [Yahoo! Finance]
11/6
04:01 pm
maze
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Medium
Report
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
11/6
08:16 am
maze
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week [Yahoo! Finance]
Low
Report
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week [Yahoo! Finance]
11/6
07:00 am
maze
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
Low
Report
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
11/4
07:00 am
maze
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
Low
Report
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
10/6
07:23 am
maze
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors [Yahoo! Finance]
Low
Report
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors [Yahoo! Finance]
10/6
07:00 am
maze
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Low
Report
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
10/4
10:21 am
maze
Maze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price Surge [Yahoo! Finance]
Low
Report
Maze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price Surge [Yahoo! Finance]
9/29
08:52 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $37.00. They now have an "overweight" rating on the stock.
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $37.00. They now have an "overweight" rating on the stock.
9/19
04:16 pm
maze
Maze Therapeutics, Inc. (MAZE): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Maze Therapeutics, Inc. (MAZE): A Bull Case Theory [Yahoo! Finance]
9/18
08:09 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
9/15
08:47 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at Guggenheim from $19.00 to $34.00. They now have a "buy" rating on the stock.
Low
Report
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at Guggenheim from $19.00 to $34.00. They now have a "buy" rating on the stock.
9/12
08:23 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at HC Wainwright from $34.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at HC Wainwright from $34.00 to $50.00. They now have a "buy" rating on the stock.
9/12
08:03 am
maze
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $30.00 to $37.00. They now have a "buy" rating on the stock.
Medium
Report
Maze Therapeutics (NASDAQ:MAZE) had its price target raised by analysts at BTIG Research from $30.00 to $37.00. They now have a "buy" rating on the stock.
9/11
07:28 pm
maze
Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript) [Seeking Alpha]
Medium
Report
Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript) [Seeking Alpha]
9/11
07:54 am
maze
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement [Yahoo! Finance]
Medium
Report
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement [Yahoo! Finance]
9/11
07:45 am
maze
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) [Yahoo! Finance]
Medium
Report
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) [Yahoo! Finance]
9/11
07:35 am
maze
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
High
Report
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement